0001262463-21-000305.txt : 20210701 0001262463-21-000305.hdr.sgml : 20210701 20210630184906 ACCESSION NUMBER: 0001262463-21-000305 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210628 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210701 DATE AS OF CHANGE: 20210630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Healthtech Solutions, Inc./UT CENTRAL INDEX KEY: 0001307624 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 842528660 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51012 FILM NUMBER: 211063333 BUSINESS ADDRESS: STREET 1: 181 DANTE AVENUE CITY: TUCKAHOE STATE: NY ZIP: 10707 BUSINESS PHONE: 844-926-3399 MAIL ADDRESS: STREET 1: 181 DANTE AVENUE CITY: TUCKAHOE STATE: NY ZIP: 10707 FORMER COMPANY: FORMER CONFORMED NAME: HYB Holding Corp. DATE OF NAME CHANGE: 20200319 FORMER COMPANY: FORMER CONFORMED NAME: XINYINHAI TECHNOLOGY, LTD. DATE OF NAME CHANGE: 20061016 FORMER COMPANY: FORMER CONFORMED NAME: IRON STAR DEVELOPMENT, INC. DATE OF NAME CHANGE: 20041102 8-K 1 hltt8k62821.htm FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 28, 2021

______________

HEALTHTECH SOLUTIONS, INC./UT

(Exact name of registrant as specified in its charter)

______________

Utah	0-51012	84-2528660
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

181 Dante Avenue, Tuckahoe, New York 10707

(Address of Principal Executive Office) (Zip Code)

844-926-3399

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 5.02

APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

On June 28, 2021 the Registrant's Board of Directors:

appointed Ryan M. Salomone to serve on the Registrant's Board of Directors

amended the Registrant's Executive Employment Agreement with Edward Swanson, the Registrant's Chief Executive Officer; and

elected Bradley K. Mathis to replace Manuel Iglesias as the Registrant's Chief Operating Officer. Mr. Iglesias continues as the Registrant's President.

On July 1, 2021, the Registrant issued a press release regarding the three executives, a copy of which is an exhibit to this Report.

Information regarding the three executives follows:

Ryan M. Salomone, Director

Ryan M. Salomone. Mr. Salomone has been appointed to the Board in order that he may contribute his 16 years of experience as an investment professional performing due diligence, risk assessment and valuation analysis on healthcare companies in the therapeutic and device space, as well as his array of relationships with industry professionals. Since 2020, Mr. Salomone has been employed as Chief Investment Officer for Twin Keel Capital, an investment fund that he co-funded. Since 2020, Mr. Salomone has also been engaged as a Consultant to PolarityTE, Inc. (NASDAQ: PTE), a biotech company to which Mr. Salomone contributes both investor relations and market analysis expertise. From 2005 through 2020, Mr. Salomone was employed by Fidelity Institutional Asset Management, completing his tenure as Senior Healthcare Analyst. In 2005 Mr. Salomone was awarded a B.B.A. degree by the Ross School of Business at the University of Michigan. He is 39 years old.

The Registrant entered into a Director Agreement with Mr. Salomone, which is applicable throughout his tenure on the Board. The Registrant agreed to pay Mr. Salomone a fee for his service of $50,000 per year, payable at Mr. Salomone's discretion in cash or common stock at market value. In addition, upon execution of the Director Agreement, the Registrant awarded 500,000 shares of restricted common stock to Mr. Salomone, which will vest over a three year period of service on the Board. The award agreement provides that whenever Mr. Salomone is re-elected to the Board at an annual meeting of the shareholders, the Registrant will grant him additional restricted shares equal to 0.25% of the fully diluted outstanding shares.

Edward Swanson, Chief Executive Officer

The Registrant amended and restated its Executive Employment Agreement with Dr. Swanson. The Amendment modified the terms under which Mr. Swanson will be eligible for severance pay. In addition, upon execution of the Amendment, the Registrant awarded one million shares of restricted common stock to Dr. Swanson, which will vest over a three year period. The award agreement provides that on each annual renewal of Mr. Swanson's employment, the Registrant will grant him additional restricted shares equal to 0.5% of the fully diluted outstanding shares.

Bradley K. Mathis, Chief Operating Officer

Bradley K. Mathis. Mr. Mathis is an experienced commercialization executive with over 30 years of service in the biotech and pharmaceutical industries. From 2019 to 2021 Mr. Mathis was employed as Vice President and General Manager of Argenx, a biotech start-up focused on antibody technologies for severe immune disorders. From 2018 to 2019 Mr. Mathis was General Manager for Orchard Therapeutics, and from 2017 to 2018 General Manager for Sucampo, in each case responsible for U.S. operations, including sales, marketing, market access, diagnostics and clinical thought leader liaison teams. From 2007 to 2017, Mr. Mathis was employed by Alexion, a biotech enterprise, where he started as a Regional Account Manager and rose to be Executive Director of a 130 person U.S. Compliment Team. In 1989 Mr. Mathis was awarded a B.B.A. degree by Texas Tech University. He is 55 years old.

The Registrant entered into an Executive Employment Agreement with Mr. Mathis, which provides for him to serve as the Registrant's COO for a term of one year, subject to automatic annual renewals unless terminated. The Registrant will pay Mr. Mathis a salary of $250,000 per year, and Mr. Mathis will be eligible for a bonus of up to 50% of his salary if criteria for the bonus set by the Registrant's Board of Directors are achieved. Upon execution of the Executive Employment Agreement, the Registrant awarded one million shares of restricted common stock to Mr. Mathis, which will vest over a three year period. The award agreement provides that on each annual renewal of Mr. Mathis' employment, the Registrant will grant him additional restricted shares equal to 0.5% of the fully diluted outstanding shares.

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS

Exhibits

10-a	Director Agreement dated June 28, 2021 between Healthtech Solutions, Inc. and Ryan Salomone
10-b	Executive Employment Agreement dated June 28, 2021 between Healthtech Solutions, Inc. and Edward Swanson
10-c	Executive Employment Agreement dated June 28, 2021 between Healthtech Solutions, Inc. and Bradley K. Mathis
99.1	Press Release dated July 1, 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Healthtech Solutions, Inc.

Date: July 1, 2021

By:

/s/ Edward Swanson

Edward Swanson, Chief Executive Officer

EX-10 2 ex10a.htm EXHIBIT 10A

DIRECTOR AGREEMENT

This DIRECTOR AGREEMENT (the “Agreement”) is dated June 28, 2021 by and between HEALTHTECH SOLUTIONS, INC., a Utah corporation (the “Company”), and RYAN SALOMONE, an individual resident of the State of Massachusetts (the “Director”).

WHEREAS, the Company appointed the Director effective as of the date hereof (the “Effective Date”) and desires to enter into an agreement with the Director with respect to such appointment; and

WHEREAS, the Director is willing to accept such appointment and to serve the Company on the terms set forth herein and in accordance with the provisions of this Agreement.

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties hereto agree as follows:

1. Position. Subject to the terms and provisions of this Agreement, the Company shall cause the Director to be appointed as a member of the Company's Board of Directors, and the Director hereby agrees to serve the Company in such position upon the terms and conditions hereinafter set forth, provided, however, that the Director’s continued service on the Board of Directors of the Company (the “Board”) after the initial term on the Board, which shall end upon the next annual meeting of the stockholders of the Company, shall be subject to approval by the Company’s stockholders.

2. Duties. During the Directorship Term (as defined herein), the Director shall perform such duties and responsibilities as are customarily performed by a Director, and shall have all responsibilities of a Director imposed by Utah or other applicable law, the Company's Articles of Incorporation and Bylaws, each as amended, including:

using best efforts to attend scheduled meetings of the Board;

serving on committees of the Board as reasonably requested by the Board;

participating as a full voting member of the Board in setting overall objectives, approving plans and programs of operation, formulating general policies, offering advice and counsel, and reviewing management performance; and

representing the shareholders and the interests of the Company as a fiduciary.

3. Compensation.

(a) Fee. The Company shall pay the Director a fee for services hereunder of Fifty Thousand Dollars ($50,000) per annum (the “Board Compensation”) to be paid in equal quarterly installments of Twelve Thousand Five Hundred Dollars ($12,500) (the “Quarterly Payments”) beginning with the initial payment on June 30, 2021. Following the Initial Payment, Quarterly Payments shall be due on the last business day of each September, December, March and June in the Directorship Term hereof (the “Payment Dates”). The Board Compensation shall be paid either in readily available funds or fully paid, validly issued and non-assessable common stock of the Company (the “Common Stock”), at the sole option of the Board Member, to be exercised by written notice to the Company on or prior to the Payment Date, failing which the Board Compensation shall be paid in cash. In the event that a Quarterly Payment is to be remitted in Common Stock, the number of shares shall be determined by dividing the Quarterly Payment by the closing sale price of the Common Stock on the trading day immediately preceding the applicable Payment Date, as reported by the principal trading market for the Common Stock.

(b) Restricted Stock. The Director shall be granted five hundred thousand (500,000) shares of restricted stock, to be granted promptly after the execution of this Agreement pursuant to the Restricted Stock Award Agreement in the form annexed hereto as Appendix A. In addition, the Director shall be granted shares of restricted stock in an amount equal to 0.25% of the fully diluted share count (including any and all outstanding common stock plus convertible securities, including convertible preferred shares, convertible debentures, granted stock options both vested and unvested, and warrants), following each annual stockholders meeting if re-elected as a Director of the Board by the stockholders of the Company (the “Re-Election Award”), the first grant of which will be made if re-elected at the first annual stockholders meeting that occurs at least 12 months after the Effective Date. Upon receipt of a Re-Election Award, the Company shall enter into a new restricted stock award agreement that separately outlines the terms and conditions of the Re-Election Award.

(c) Independent Contractor. The Director’s legal status during the Directorship Term shall be that of an independent contractor and not, for any purpose, that of an employee or agent with authority to bind the Company in any respect. All payments and other consideration made or provided to the Director under this Section 3 shall be made or provided without withholding or deduction of any kind, and the Director shall assume sole responsibility for discharging all tax or other obligations associated therewith.

(d) Expense Reimbursements. During the Directorship Term, the Company shall reimburse the Director for all reasonable out-of-pocket expenses incurred by the Director in attending any in-person meetings, provided that the Director complies with the generally applicable policies, practices and procedures of the Company for submission of expense reports, receipts or similar documentation of such expenses. Any reimbursements for any single item of expense in excess of $1,000 or for aggregate expenses during any thirty-day period in excess of $2,500 must be approved in advance by the Company.

4. Directorship Term. The “Directorship Term,” as used in this Agreement, shall mean the period commencing on the Effective Date and terminating on the earlier of the date of the next annual stockholders meeting and the earliest of the following to occur: (a) the death of the Director; (b) the termination of the Director from his membership on the Board by the mutual agreement of the Company and the Director; (c) the removal of the Director from the Board by the stockholders of the Company; and (d) the resignation by the Director from the Board. In the event that the Director is re-elected at a stockholders meeting, then the Agreement shall be extended, and the term "next annual stockholders meeting" in the preceding sentence shall mean the first annual stockholders meeting occurring after the re-election.

5. Director’s Representation and Acknowledgment. The Director represents to the Company that his execution and performance of this Agreement shall not be in violation of any agreement or obligation (whether or not written) that he may have with or to any person or entity, including without limitation, any prior or current employer. The Director hereby acknowledges and agrees that this Agreement (and any other agreement or obligation referred to herein) shall be an obligation solely of the Company, and the Director shall have no recourse whatsoever against any stockholder of the Company or any of their respective affiliates with regard to this Agreement.

6. Director Covenants.

(a) Unauthorized Disclosure. The Director agrees and understands that in the Director’s position with the Company, the Director will be exposed to and receive information relating to the confidential affairs of the Company, including, but not limited to, research programs and results, data, scientific concepts, inventions and technical information (collectively, "Company IP"), business and marketing plans, strategies, customer information, other information concerning the Company’s research and development activities, products, promotions, development, financing, expansion plans, business policies and practices, and other forms of information considered by the Company to be confidential and in the nature of trade secrets. The Director agrees that during the Directorship Term and thereafter, the Director will keep such information confidential and will not disclose such information, either directly or indirectly, to any third person or entity without the prior written consent of the Company; provided, however, that (i) the Director shall have no such obligation to the extent such information is or becomes publicly known or generally known in the Company’s industry other than as a result of the Director’s breach of his obligations hereunder and (ii) the Director may, after giving prior notice to the Company to the extent practicable under the circumstances, disclose such information to the extent required by applicable laws or governmental regulations or judicial or regulatory process. This confidentiality covenant has no temporal, geographical or territorial restriction. Upon termination of the Directorship Term, the Director will promptly return to the Company and/or destroy at the Company’s direction all property, keys, notes, memoranda, writings, lists, files, reports, customer lists, correspondence, tapes, disks, cards, surveys, maps, logs, machines, technical data, other product or document, and any summary or compilation of the foregoing, in whatever form, including, without limitation, in electronic form, which has been produced by, received by or otherwise submitted to the Director in the course or otherwise as a result of the Director’s position with the Company during or prior to the Directorship Term, provided that the Company shall retain such materials and make them available to the Director if requested by him in connection with any litigation against the Director under circumstances in which (i) the Director demonstrates to the reasonable satisfaction of the Company that the materials are useful to his defense in the litigation and (ii) the confidentiality of the materials is preserved to the reasonable satisfaction of the Company.

(b) Non-Solicitation. During the Directorship Term and for a period of three (3) years thereafter, the Director shall not interfere with the Company’s relationship with, or endeavor to entice away from the Company, any person who, on the date of the termination of the Directorship Term and/or at any time during the one year period prior to the termination of the Directorship Term, was an employee or customer of the Company or otherwise had a material business relationship with the Company.

(c) No Conflict. Director will not engage in any activity that creates an actual or perceived conflict of interest with the Company, regardless of whether such activity is prohibited by Company’s conflict of interest guidelines or this Agreement, and Director agrees to notify the Board of Directors before engaging in any activity that could reasonably be assumed to create a potential conflict of interest with Company. Director shall not engage in any activity that is in direct competition with the Company or serve in any capacity (including, but not limited to, as an employee, consultant, advisor or director) in any company or entity that competes directly or indirectly with the Company without the approval of the Board of Directors. Nothing in this Section 6(c) shall prohibit the Director from being (i) a stockholder in a mutual fund or a diversified investment company or (ii) a passive owner of not more than three percent of the outstanding stock of any class of securities of a corporation, which are publicly traded, so long as the Director has no active participation in the business of such corporation.

(d) Remedies. The Director agrees that any breach of the terms of this Section 6 would result in irreparable injury and damage to the Company for which the Company would have no adequate remedy at law; the Director therefore also agrees that in the event of said breach or any threat of breach, the Company shall be entitled to an immediate injunction and restraining order to prevent such breach and/or threatened breach and/or continued breach by the Director and/or any and all entities acting for and/or with the Director, without having to prove damages or paying a bond, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms of this paragraph shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof, including, but not limited to, the recovery of damages from the Director. The Director acknowledges that the Company would not have entered into this Agreement had the Director not agreed to the provisions of this Section 6.

(e) The provisions of this Section 6 shall survive any termination of the Directorship Term, and the existence of any claim or cause of action by the Director against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of the covenants and agreements of this Section 6.

7. Work Product. In the event that the Director participates in any of the Company's research and development activities ("Company Practice"), or pursues research and development activities that are premised on, or extensions of, in whole or in part, research or development activities carried on by the Company ("Derivative Practice"), then the Company shall own all right, title and interest relating to all inventions, improvements, discoveries, methods, developments, software, and works of authorship, whether patentable or not, which are created, made, conceived or reduced to practice by the Director or jointly with others and are either materially derivative from Company Practice or Derivative Practice or involved Director's use of Company IP (collectively, “Developments”). The Director agrees to make full and prompt disclosure to the Company of all Developments and provide all Developments and all materials and concepts relating to Developments to the Company. Director hereby assigns to the Company or its designee all of the Director's right, title and interest in and to any and all Developments. The Director agrees to cooperate fully with the Company, both during and after the term of this Agreement, with respect to the procurement, maintenance and enforcement of intellectual property rights (both in the United States and foreign countries) relating to any Developments. The Director shall sign all documents which may be necessary or desirable in order to protect the Company's rights in and to any Developments, and the Director hereby irrevocably designates and appoints each officer of the Company as the Director's agent and attorney-in-fact to execute any such documents on the Director's behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Developments.

Notwithstanding anything to the contrary above, this Section 7 does not apply to an invention for which no equipment, supplies, facility of the Company or Company IP was used, unless the invention relates to the business of the Company or to the Company's actual or demonstrably anticipated research or development, or the invention results from any work performed by the Director for the Company.

8. Indemnification; Insurance. Simultaneous with the execution of this Director Agreement, the Company and the Director will execute an Indemnification Agreement providing for the Company to indemnify the Director for his activities as a member of the Board or any committee of the Board to the fullest extent permitted under the laws of the State of Utah. The Company agrees that at all times during the Directorship Term, the Company will maintain in full force and effect a Directors and Officers liability insurance policy with standard terms of coverage and a per event coverage limit of not less than Two Million Dollars ($2,000,000).

9. Notices. Every notice relating to this Agreement shall be in writing and shall be given by personal delivery or by email with a read receipt; to:

If to the Company:

Healthtech Solutions, Inc.

181 Dante Avenue

Tuckahoe, NY 10707

Email: rbrantl21@gmail.com

If to the Director:

Ryan Salomone

_____________________

Email: _______________

Either of the parties hereto may change their address for purposes of notice hereunder by giving notice in writing to such other party pursuant to this Section 9.

10. Binding Effect/Assignment. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, executors, personal representatives, estates, successors (including, without limitation, by way of merger) and assigns. Notwithstanding the provisions of the immediately preceding sentence, neither the Director nor the Company shall assign all or any portion of this Agreement without the prior written consent of the other party.

11. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Utah, without reference to the principles of conflict of laws. All actions and proceedings arising out of or relating to this Agreement shall be heard and determined in any court in New York County, New York and the parties hereto hereby consent to the jurisdiction of such courts in any such action or proceeding; provided, however, that neither party shall commence any such action or proceeding unless prior thereto the parties have in good faith attempted to resolve the claim, dispute or cause of action which is the subject of such action or proceeding through mediation by an independent third party.

12. Modifications. Neither this Agreement nor any provision hereof may be modified, altered, amended or waived except by an instrument in writing duly signed by the party to be charged.

13 Counterparts. This Agreement may be executed in two counterparts, each of which shall be deemed to be an original but both of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Company has caused this Director Agreement to be executed by authority of its Board of Directors, and the Director has hereunto set his hand, on the day and year first above written.

	HEALTHTECH SOLUTIONS, INC.

	/s/ Edward Swanson
	Edward Swanson
	Chief Executive Officer

	DIRECTOR

	/s/ Ryan Salomone
	Ryan Salomone

EX-10 3 ex10b.htm EXHIBIT 10B

EXECUTIVE EMPLOYMENT AGREEMENT

This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 28th day of June, 2021 (the "Effective Date") by and between Healthtech Solutions, Inc. a Utah corporation with a principal business address at 181 Dante Avenue, Tuckahoe, NY 10707 (the “Company”) and Edward Swanson, an individual residing in the state of Pennsylvania (“Executive”).

W I T N E S S E T H:

WHEREAS, the Executive desires to be employed by the Company as its Chief Executive Officer and the Company wishes to employ the Executive in such capacities, in each case, commencing on and as of the Effective Date.

NOW, THEREFORE, in consideration of the foregoing and their respective covenants and agreements contained in this document, the Company and the Executive hereby agree as follows:

1. Employment and Duties. The Company agrees to employ and the Executive agrees to serve as the Company’s Chief Executive Officer. Executive shall have all powers, duties, responsibilities and authority that are assigned by the Company Board of Directors (the “Board”), set forth in the Company's Bylaws, or that are implicitly assigned to the Chief Executive Officer by the Revised Business Corporation Act of the State of Utah.

The Executive shall devote his full-time efforts and services to the business and affairs of the Company and its subsidiaries, either formed or to be formed in the future. Nothing in this Section 1 shall prohibit the Executive from: (A) serving as a director or member of any other board, committee thereof of any other entity or organization; (B) delivering lectures, fulfilling speaking engagements, and any writing or publication relating to his area of expertise, subject to prior approval of the Board, not to be reasonably withheld; (C) serving as a director or trustee of any governmental, charitable or educational organization; (D) engaging in additional activities in connection with personal investments and community affairs, including, without limitation, professional or charitable or similar organization committees, boards, memberships or similar associations or affiliations, or (E) performing advisory activities, provided, however, such activities are not in competition with the business and affairs of the Company or would tend to cast executive of the Company in a negative light in the reasonable judgment of the Board.

2. Term. The term of this Agreement shall commence on the Effective Date and shall continue for a period of one (1) year following the Effective Date and shall be automatically renewed for successive one (1) year periods thereafter unless either party provides the other party with written notice of his or its intention not to renew this Agreement at least three (3) months prior to the expiration of the initial term or any renewal term of this Agreement. “Employment Period” shall mean the initial one (1) year term plus all one (1) year renewals, if any.

3. Place of Employment. The Executive’s services shall be performed at such location or locations as the Executive shall determine, in his sole discretion.

4. Salary and Board Fees. The Company agrees to pay the Executive a base salary (“Base Salary”) of $250,000 per annum for his services hereunder. Annual adjustments after the first year of the Employment Period shall be subject to the discretion of the Board. (Base Salary and any adjusted salary shall be identified herein as "Salary".) Executive's Salary shall be paid in periodic installments in accordance with the Company’s regular payroll practices. Executive shall, subject to policies and procedures of the Company’s Board, be eligible for additional fees for service on the Company’s Board, if applicable.

5. Incentive Compensation and Bonuses.

(a) Annual Bonus: Within sixty (60) days after the Effective Date, the Board (or the Compensation Committee thereof, if any) shall determine criteria for measuring Executive's accomplishments during the remainder of the 2021 fiscal year, and prior to each subsequent fiscal year during the Employment Period the Board shall likewise determine such criteria for the coming fiscal year. For each fiscal year during the Employment Period, the Executive shall be eligible to receive a bonus (the "Annual Bonus") in the amount of up to fifty percent (50%) of his annual salary, as determined by the Board, based upon Executive's accomplishment of the aforesaid criteria. The Annual Bonus shall be paid by the Company to the Executive promptly after its determination that the relevant criteria have been satisfied, it being understood that the attainment of any financial targets associated with any bonus shall not be determined until following the completion of the Company’s annual audit and public announcement of such results and shall be paid promptly following the Company’s announcement of earnings.

(b) Equity Awards and Incentive Compensation: During the term of employment, the Executive shall be eligible to participate in any equity-based incentive compensation plan or program adopted by the Company (such awards under such plan or program, the “Share Awards”) as the Compensation Committee or Board may from time to time determine. Share Awards shall be subject to applicable plan terms and conditions. And any additional terms and conditions as determined by the Compensation Committee or the Board. On the Effective Date, the Board of Directors of Parent shall award and reserve for issuance 1,000,000 shares of common stock to Executive and enter into a Restricted Stock Award agreement (the “RS Agreement”) on the effective date. If this Agreement is renewed pursuant to Section 2, the Board of Directors of Parent shall grant the Executive shares of restricted stock in an amount equal to 0.5% of the fully diluted share count (including any and all outstanding common stock plus convertible securities, including convertible preferred shares, convertible debentures, granted stock options both vested and unvested, and warrants) on the effective date of every one (1) year renewal with further terms and conditions within the RS Agreement. Additionally, on the Effective Date, the Board of Directors of Parent shall enter into a Performance Restricted Share Unit Agreement (the “PSU Agreement”).

6. Severance Compensation:

Upon termination of employment, prior to the expiration of the Employment Period, for any reason other than for cause, as defined below, and subject to the provisions of Section 11(c)(3), the Executive shall be entitled to: (A) Six (6) months of his annual Base Salary be paid according to Section 4; (B) any and all reasonable expenses paid or incurred by the Executive in connection with and related to the performance of his duties and responsibilities for the Company during the period ending on the termination date to be paid according to Section 8; (C) any accrued but unused vacation time through the termination date in accordance with Company policy; and (D) all Share Awards earned and vested prior to termination. With respect to any Share Awards held by the Executive as of his death that are not vested and exercisable as of such date, the Company shall fully accelerate the vesting and exercisability of such Share Awards, so that all such Share Awards shall be fully vested and exercisable as of the Executive’s death, such options (as well as any Share Awards that previously became vested and exercisable) to remain exercisable, notwithstanding anything in any other agreement governing such options, until the earlier of (A) a period of one (1) year after the Executive’s death or (B) the original term of the option, if such Share Awards is an option.

The Executive may continue coverage with respect to the Company’s group health plans as permitted by the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) for himself and each of his “Qualified Beneficiaries” as defined by COBRA (“COBRA Coverage”). The Company shall reimburse the amount of any COBRA premium paid for COBRA Coverage timely elected by and for the Executive and any Qualified Beneficiary of the Executive, and not otherwise reimbursed, during the period that ends on the earliest of (x) the date the Executive or the Qualified Beneficiary, as the case may be, ceases to be eligible for COBRA Coverage, (y) the last day of the consecutive eighteen (18) month period following the date of termination of the Executive’s employment and (z) the date the Executive or the Qualified Beneficiary, as the case may be, is covered by another group health plan. To reimburse any COBRA premium payment under this paragraph, the Company must receive documentation of the COBRA premium payment within ninety (90) days of its payment.

7. Clawback Rights. The Annual Bonus and any and all stock based compensation (such as options and equity awards) (collectively, the “Clawback Benefits”) shall be subject to “Clawback Rights” as follows. During the period that the Executive is employed by the Company and for a period of three (3) years following the Employment Period, if there is a restatement by the Company of any financial results on the basis of which any Clawback Benefits to the Executive have been determined, the Executive shall repay to the Company the amount by which the amount of Clawback Benefits paid exceeded the amount to which Executive would have been entitled, based on the Company’s restated financial information. The calculation of the revised Clawback Benefits amount shall be determined by the Compensation Committee in good faith and in accordance with applicable law. All determinations by the Compensation Committee with respect to the Clawback Rights shall be final and binding on the Company and the Executive. The Clawback Rights shall terminate following a Change of Control as defined in Section 11(f). For purposes of this Section 7, a restatement of financial results that requires a repayment of a portion of the Clawback Benefits amounts shall mean a restatement resulting from material non-compliance of the Company with any financial reporting requirement under the federal securities laws and shall not include a restatement of financial results resulting from subsequent changes in accounting pronouncements or requirements which were not in effect on the date the financial statements were originally prepared (“Restatements”). The parties acknowledge it is their intention that the foregoing Clawback Rights as relates to Restatements conform in all respects to such regulations as may be promulgated pursuant to the provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (“Dodd-Frank Act”) relating to recovery of “incentive-based” compensation. Accordingly, the terms and provisions of this Agreement shall be deemed automatically amended from time to time to assure compliance with the Dodd-Frank Act and such rules and regulations as hereafter may be adopted and in effect.

8. Expenses. The Executive shall be entitled to prompt reimbursement by the Company for all reasonable ordinary and necessary travel, entertainment, and other expenses incurred by the Executive while employed (in accordance with the policies and procedures established by the Company for its senior executive officers) in the performance of his duties and responsibilities under this Agreement; provided, that the Executive shall properly account for such expenses in accordance with Company policies and procedures. Any individual expenses (including expenses such as travel that are a single expense with multiple components) in an amount exceeding Two Thousand Five Hundred Dollars ($2,500) shall require approval by the Board or such officer of the Company designated by the Board to serve this purpose.

9. Other Benefits. During the term of this Agreement, the Executive shall be eligible to participate in incentive, stock purchase, savings, retirement (401(k)), and welfare benefit plans, including, without limitation, health, medical, dental, vision, life (including accidental death and dismemberment) and disability insurance plans (collectively, “Benefit Plans”), in substantially the same manner and at substantially the same levels as the Company makes such opportunities available to the Company’s managerial or salaried executive employees and/or its senior executives.

10. Vacation. During the term of this Agreement, the Executive shall be entitled to accrue, on a monthly basis, eighteen (18) paid vacation days per year, provided that Executive's total accrued vacation shall not exceed thirty (30) days. Should Executive's accrued vacation time reach thirty days, Executive will cease to accrue vacation until Executive's accrued vacation time falls below that level. Vacation shall be taken at such times as are mutually convenient to the Executive and the Company, and no more than ten (10) consecutive days shall be taken at any one time without Company approval in advance.

11. Termination of Employment:

(a) Death. If the Executive dies during the Employment Period, this Agreement and the Executive’s employment with the Company shall automatically terminate and the Company’s obligations to the Executive’s estate and to the Executive’s Qualified Beneficiaries shall be those set forth in Section 6 regarding severance compensation.

(b) Disability. In the event that, during the term of this Agreement the Executive shall be prevented from performing his essential functions hereunder to the full extent required by the Company by reason of Disability (as defined below), the Board shall be entitled to terminate this Agreement and the Executive’s employment hereunder. The Company’s obligation to the Executive under such circumstances shall be those set forth in Section 6 regarding severance compensation. For purposes of this Agreement, “Disability” shall mean a physical or mental disability that prevents the performance by the Executive, with or without reasonable accommodation, of his essential functions hereunder for an aggregate of ninety (90) days or longer during any twelve (12) consecutive months. The determination of the Executive’s Disability shall be made by an independent physician who is reasonably acceptable to the Company and the Executive (or his representative), shall be final and binding on the parties hereto and shall be made taking into account such competent medical evidence as shall be presented to such independent physician by the Executive and/or the Company or by any physician or group of physicians or other competent medical experts employed by the Executive and/or the Company to advise such independent physician.

(1) At any time during the Employment Period, the Company may terminate this Agreement and the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean: (a) the willful and continued failure of the Executive to perform substantially his duties and responsibilities to the Company (other than any such failure resulting from the Executive’s death or Disability) after a written demand by the Board for substantial performance is delivered to the Executive by the Company, which specifically identifies the manner in which the Board believes that the Executive has not substantially performed his duties and responsibilities, which willful and continued failure is not cured by the Executive within thirty (30) days following his receipt of such written demand; (b) the conviction of, or plea of guilty or nolo contendere to, a felony, or (c) fraud, dishonesty or gross misconduct which is materially and demonstratively injurious to the Company. Termination under clauses (b) or (c) of this Section 11(c)(1) shall not be subject to cure.

(2) For purposes of this Section 11(c), no act, or failure to act, on the part of the Executive shall be considered “willful” unless done, or omitted to be done, by him in bad faith and without reasonable belief that his action or omission was in, or not opposed to, the best interest of the Company. Between the time the Executive receives written demand regarding substantial performance, as set forth in subparagraph (1) above, and prior to an actual termination for Cause, the Executive will be entitled to appear (with counsel, if he so chooses) before the full Board to present information regarding his views on the Cause event(s). After such hearing, termination for Cause must be approved by a majority vote of the full Board (other than the Executive). After providing the written demand regarding substantial performance, the Board may suspend the Executive with full pay and benefits until a final determination by the full Board has been made.

(3) Upon termination of this Agreement for Cause, the Company shall have no further obligations or liability to the Executive or his heirs, administrators or executors with respect to compensation and benefits thereafter, except for the obligation to pay the Executive any Salary earned through the date of termination to be paid according to Section 4; any Annual Bonus that has accrued but remains unpaid; reimbursement of any expenses payable pursuant to Section 8; and any accrued but unused vacation time through the termination date in accordance with Company policy. The Company shall deduct, from all payments made hereunder, all applicable taxes, including income tax, FICA and FUTA, and other appropriate deductions, including expenses.

(d) For Good Reason or a Change of Control or Without Cause.

(1) At any time during the term of this Agreement and subject to the conditions set forth in Section 11(d)(2) below the Executive may terminate this Agreement and the Executive’s employment with the Company for “Good Reason” or for a “Change of Control” (as defined in Section 11(f)). For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following events without Executive’s consent: (A) the assignment to the Executive of duties that are significantly different from, and/or that result in a substantial diminution of, the duties that he assumed on the Effective Date (including reporting to anyone other than solely and directly to the Board); (B) the assignment to the Executive of a title that is different from and subordinate to the title Chief Executive Officer of the Company; provided, however, for the absence of doubt following a Change of Control, should the Executive be required to serve in a diminished capacity in a division or unit of another entity (including the acquiring entity), such event shall constitute Good Reason regardless of the title of the Executive in such acquiring company, division or unit; or (C) material breach by the Company of this Agreement.

(2) The Executive shall not be entitled to terminate this Agreement for Good Reason unless and until he shall have delivered written notice to the Company within ninety (90) days of the date upon which the facts giving rise to Good Reason occurred of his intention to terminate this Agreement and his employment with the Company for Good Reason, which notice specifies in reasonable detail the circumstances claimed to provide the basis for such termination for Good Reason, and the Company shall not have eliminated the circumstances constituting Good Reason within thirty (30) days of its receipt from the Executive of such written notice. In the event the Executive elects to terminate this Agreement for Good Reason in accordance with Section 11(d)(1), such election must be made within the twenty-four (24) months following the initial existence of one or more of the conditions constituting Good Reason as provided in Section 11(d)(1). In the event the Executive elects to terminate this Agreement for a Change in Control in accordance with Section 11(d)(1), such election must be made within one hundred eighty (180) days of the occurrence of the Change of Control.

(3) In the event that the Executive terminates this Agreement and his employment with the Company for Good Reason or for a Change of Control or the Company terminates this Agreement and the Executive’s employment with the Company without Cause, the Company shall pay or provide to the Executive (or, following his death, to the Executive’s heirs, administrators or executors) the severance compensation set forth in Section 6 above. The Company shall deduct, from all payments made hereunder, all applicable taxes, including income tax, FICA and FUTA, and other appropriate deductions.

(4) The Executive shall not be required to mitigate the amount of any payment provided for in this Section 11(d) by seeking other employment or otherwise, nor shall the amount of any payment provided for in this Section 11(d) be reduced by any compensation earned by the Executive as the result of employment by another employer or business or by profits earned by the Executive from any other source at any time before and after the termination date. The Company’s obligation to make any payment pursuant to, and otherwise to perform its obligations under, this Agreement shall not be affected by any offset, counterclaim or other right that the Company may have against the Executive for any reason.

(e) Without “Good Reason” by the Executive. At any time during the term of this Agreement, the Executive shall be entitled to terminate this Agreement and the Executive’s employment with the Company without Good Reason and other than for a Change of Control by providing prior written notice of at least thirty (30) days to the Company. Upon termination by the Executive of this Agreement or the Executive’s employment with the Company without Good Reason and other than for a Change of Control, the Company shall have no further obligations or liability to the Executive or his heirs, administrators or executors with respect to compensation and benefits thereafter, except for the obligation to pay the Executive any Salary earned through the date of termination to be paid according to Section 4; reimbursement of any expenses payable pursuant to Section 8; and any accrued but unused vacation time through the termination date in accordance with Company policy. The Company shall deduct, from all payments made hereunder, all applicable taxes, including income tax, FICA and FUTA, and other appropriate deductions.

(f) Change of Control. For purposes of this Agreement, “Change of Control” shall mean the occurrence of any one or more of the following: (i) the accumulation (if over time, in any consecutive twelve (12) month period), whether directly, indirectly, beneficially or of record, by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) of more than fifty percent (50%) of the outstanding shares of Common Stock of the Company (including equity instruments convertible without payment into Common Stock), whether by merger, consolidation, sale or other transfer of shares of Common Stock (other than a merger or consolidation where the stockholders of the Company prior to the merger or consolidation are the holders of a majority of the voting securities of the entity that survives such merger or consolidation), (ii) a sale of all or substantially all of the assets of the Company or (iii) during any period of twelve (12) consecutive months, the individuals who, at the beginning of such period, constitute the Board, and any new Board member whose election by the Board or nomination for election by the Company’s owners was approved by a vote of at least two-thirds (2/3) of the members of the Board then still in office who either were members of the Board at the beginning of the twelve (12) month period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the Board; provided that the following acquisitions shall not constitute a Change of Control for the purposes of this Agreement: any acquisition of Common Stock or securities convertible into Common Stock by any employee benefit plan (or related trust) sponsored by or maintained by the Company.

12. Confidential Information.

(a) Disclosure of Confidential Information. The Executive recognizes, acknowledges and agrees that he have access to secret and confidential information regarding the Company, its subsidiaries and their respective businesses, including but not limited to, its research programs, research results, technologies, products, methods, formulas, software code, patents, sources of supply, customer dealings, data, know-how, trade secrets and business plans. All of such information shall be deemed "Confidential Information", provided such information is not in or does not hereafter become part of the public domain, or become available to the public generally through no fault of the Executive. The Executive acknowledges that such information is of great value to the Company, is necessary for the conduct of the Company's business, and has been and will be acquired by him in confidence. In consideration of the obligations undertaken by the Company herein, the Executive will not, at any time, during or after his employment hereunder, reveal, divulge or make known to any person, any information acquired by the Executive during the course of his employment, which is treated as confidential by the Company, and not otherwise in the public domain. The provisions of this Section 12 shall survive the termination of the Executive’s employment hereunder.

(b) The Executive affirms that he does not possess the protected trade secrets or confidential or proprietary information of any prior employer(s), and that he will not use any proprietary information of any person in providing services to the Company or its subsidiaries.

(c) In the event that the Executive’s employment with the Company terminates for any reason, the Executive shall deliver forthwith to the Company any and all originals and copies, including those in electronic or digital formats, of Confidential Information; provided, however, the Executive shall be entitled to retain (i) papers and other materials of a personal nature, including, but not limited to, photographs, correspondence, personal diaries, calendars, rolodexes and phone books, (ii) information showing his compensation or relating to reimbursement of expenses, (iii) information that he reasonably believes may be needed for tax purposes and (iv) copies of plans, programs and agreements relating to his employment, or termination thereof, with the Company. The covenants and agreements in this Section 12 shall exclude information (A) which is in the public domain through no unauthorized act or omission of Executive or (B) which becomes available to Executive on a non-confidential basis from a source other than the Company or its affiliates without breach of such source’s confidentiality or non-disclosure obligations to the Company or any of its affiliates.

13. Non-Competition and Non-Solicitation.

(a) The Executive agrees and acknowledges that the Confidential Information that the Executive will receive is valuable to the Company and that its protection and maintenance constitutes a legitimate business interest of the Company, to be protected by the non-competition restrictions set forth herein. The Executive agrees and acknowledges that the non-competition restrictions set forth herein are reasonable and necessary and do not impose undue hardship or burdens on the Executive.

(b) The Executive hereby agrees and covenants that he shall not without the prior written consent of the Company, directly or indirectly, in any capacity whatsoever, including, without limitation, as an employee, employer, consultant, principal, partner, shareholder, officer, director or any other individual or representative capacity (other than (i) as a holder of less than two (2%) percent of the outstanding securities of a company whose shares are traded on any national securities exchange or (ii) as a limited partner, passive minority interest holder in a venture capital fund, private equity fund or similar investment entity which holds or may hold an equity or debt position in portfolio companies that are competitive with the Company; provided however, that the Executive shall be precluded from serving as an operating partner, general partner, manager or governing board designee with respect to such portfolio companies), or whether on the Executive’s own behalf or on behalf of any other person or entity or otherwise howsoever, during the Term and thereafter to the extent described below:

(1) Recruit or solicit any employee of, or independent contractor engaged by the Company to leave the employment (or independent contractor relationship) thereof, whether or not any such employee or independent contractor is party to an employment agreement with the business of the Company;

(2) Attempt in any manner to solicit or accept from any customer of the Company, with whom Executive had significant contact during Executive’s employment by the Company (whether under this Agreement or otherwise), business of the kind or competitive with the business done by the Company with such customer or to persuade or attempt to persuade any such customer to cease to do business or to reduce the amount of business which such customer has customarily done or might do with the Company, or if any such customer elects to move its business to a person other than the Company, provide any services of the kind or competitive with the business of the Company for such customer, or have any discussions regarding any such service with such customer, on behalf of such other person for the purpose of competing with the business of the Company; or

(3) Interfere with any relationship, contractual or otherwise, between the Company and any other party, including, without limitation, any supplier, distributor, co-venturer or joint venturer of the Company, for the purpose of soliciting such other party to discontinue or reduce its business with the Company.

With respect to the activities described in Paragraphs (1), (2) and (3) above, the restrictions of this Section 13(b) shall continue during the Employment Period and for a period of one (1) year thereafter.

14. Work Product

(a) Except as otherwise provided in written agreement between Executive and the Company, Executive shall retain all right, title and interest in and to all inventions, developments, ideas, methods, processes, designs, analyses, reports and all similar or related information (in each case whether or not patentable), all copyrightable works, all trade secrets, confidential information and know-how, and all other intellectual property rights that were conceived, reduced to practice, developed or made by Executive prior to his Employment with the Company (“Executive’s Inventions”).

(b) Executive hereby assigns to Company all right, title and interest in and to all inventions, developments, ideas, methods, processes, designs, analyses, reports and all similar or related information (in each case whether or not patentable), all copyrightable works, all trade secrets, confidential information and know-how, and all other intellectual property rights that (x) are conceived, reduced to practice, developed or made by Executive during the Employment Period, and (y) either: (i) relate at the time of conception or reduction to practice to the Company’s business, or actual or demonstrably anticipated research or development of the Company, or (ii) result from any work performed by Executive for the Company (“Company IP”).

(c) To the extent necessary, each Party shall perform all actions reasonably requested by the other Party (whether during or after the Termination Date) to establish and confirm either Party’s ownership of Executive’s Inventions or Company IP, as applicable (including, without limitation, executing and delivering assignments, consents, powers of attorney, applications and other instruments).

(d) The provisions of this Section 14 shall survive the termination or expiration of this Agreement.

15. Miscellaneous.

(a) Neither the Executive nor the Company may assign or delegate any of their rights or duties under this Agreement without the express written consent of the other; provided, however, that the Company shall have the right to delegate its obligation of payment of all sums due to the Executive hereunder, provided that such delegation shall not relieve the Company of any of its obligations hereunder.

(b) During the term of this Agreement, the Company (i) shall indemnify and hold harmless the Executive and his heirs and representatives to the maximum extent permitted by the laws of the State of Utah and by Company’s Charter and Bylaws and (ii) shall cover the Executive under the Company’s directors’ and officers’ liability insurance on the same basis as it covers other senior executive officers and directors of the Company.

(c) This Agreement constitutes and embodies the full and complete understanding and agreement of the parties with respect to the Executive’s employment by the Company, supersedes all prior understandings and agreements, whether oral or written, between the Executive and the Company, and shall not be amended, modified or changed except by an instrument in writing executed by the party to be charged. If any provision of this Agreement, or the application thereof, shall for any reason and to any extent be invalid or unenforceable, then the remainder of this Agreement and the application of such provision to other persons or circumstances shall be interpreted so as reasonably to effect the intent of the parties hereto. The parties further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that shall achieve, to the extent possible, the economic, business and other purposes of the void or unenforceable provision. No waiver by either party of any provision or condition to be performed shall be deemed a waiver of similar or dissimilar provisions or conditions at the same time or any prior or subsequent time.

(d) This Agreement shall inure to the benefit of, be binding upon and enforceable against, the parties hereto and their respective successors, heirs, beneficiaries and permitted assigns.

(e) All notices, requests, demands and other communications required or permitted to be given hereunder shall be in writing and shall be deemed to have been duly given when personally delivered or sent by reputable national overnight delivery service (e.g., Federal Express) for overnight delivery to the party at the address set forth below, or to such other address as either party may hereafter give the other party notice of in accordance with the provisions hereof. Notices shall be deemed given on the sooner of the date actually received or one business day after deposited with an overnight delivery service for overnight delivery. The addresses of the parties for delivery of notice shall be:

To the Company:

Healthtech Solutions, Inc.

181 Dante Avenue.

Tuckahoe, NY 10707

To the Executive:

Edward Swanson

PO Box 299

Gwynedd Valley, PA 19437

(f) This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York, and each of the parties hereto irrevocably consents to the jurisdiction and venue of the federal and state courts located in the State of New York, County of New York, for any disputes arising out of this Agreement, or the Executive’s employment with the Company. The prevailing party in any dispute arising out of this Agreement shall be entitled to his or its reasonable attorney’s fees and costs.

(g) This Agreement may be executed simultaneously in counterparts, each of which shall be deemed an original, but both of which together shall constitute one of the same instrument. The parties hereto have executed this Agreement as of the date set forth above.

(h) The Executive represents and warrants to the Company, that he has the full power and authority to enter into this Agreement and to perform his obligations hereunder and that the execution and delivery of this Agreement and the performance of his obligations hereunder will not conflict with any agreement to which the Executive is a party.

(i) The Company represents and warrants to the Executive that it has the full power and authority to enter into this Agreement and to perform its obligations hereunder and that the execution and delivery of this Agreement and the performance of its obligations hereunder will not conflict with any agreement to which the Company is a party.

[Signature page follows immediately]

IN WITNESS WHEREOF, the Executive and the Company have caused this Executive Employment Agreement to be executed as of the date first above written.

HEALTHTECH SOLUTIONS, INC.

By: /s/ Manuel E. Iglesias

Manuel E. Iglesias, President

EXECUTIVE:

/s/ Edward Swanson

Edward Swanson

EX-10 4 ex10c.htm EXHIBIT 10C

EXECUTIVE EMPLOYMENT AGREEMENT

This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 28 day of June, 2021 by and between Healthtech Solutions, Inc., a corporation with a principal business address of 181 Dante Avenue, Tuckahoe, NY 10707 (the “Company”) and Bradley K. Mathis, an individual residing in the state of Pennsylvania (“Executive”). As used herein, the “Effective Date” of this Agreement shall mean the date as written above and signed below.

W I T N E S S E T H:

WHEREAS, the Executive desires to be employed by the Company as its Chief Operating Officer and the Company wishes to employ the Executive in such capacity, commencing on and as of the Effective Date.

NOW, THEREFORE, in consideration of the foregoing and their respective covenants and agreements contained in this document, the Company and the Executive hereby agree as follows:

1. Employment and Duties. The Company agrees to employ and the Executive agrees to serve as the Company’s Chief Operating Officer. The duties and responsibilities of the Executive shall include the duties and responsibilities as the Company’s Board of Directors (“Board”) may from time to time assign to the Executive.

The Executive shall devote his full-time efforts and services to the business and affairs of the Company and its subsidiaries, either formed or to be formed in the future. Nothing in this Section 1 shall prohibit the Executive from: (A) serving as a director or member of any other board or committee thereof of any other entity or organization; (B) delivering lectures, fulfilling speaking engagements, and any writing or publication relating to his area of expertise, subject to prior approval of the Board, not to be unreasonably withheld; (C) serving as a director or trustee of any governmental, charitable or educational organization; (D) engaging in additional activities in connection with personal investments and community affairs, including, without limitation, professional or charitable or similar organization committees, boards, memberships or similar associations or affiliations, or (E) performing advisory activities, provided, however, such activities are not in competition with the business and affairs of the Company or would tend to cast executive or the Company in a negative light in the reasonable judgment of the Board.

3. Place of Employment. The Executive’s services shall be performed at such location or locations as the Executive shall determine, in his sole discretion.

4. Sign On, Base Salary and Board Fees. The Company agrees to pay the Executive a (“Sign On”) bonus of $15,000.00 and a base salary (“Base Salary”) of $250,000.00 per annum for the position of Chief Operating Officer. Annual adjustments after the first year of the Employment Period shall be determined by the Board. The Base Salary shall be paid in periodic installments in accordance with the Company’s regular payroll practices. Executive shall, subject to policies and procedures of the Company’s Board, be eligible for additional fees for service on the Company’s Board, if applicable.

5. Incentive Compensation and Bonuses.

(a) Annual Bonus: For each fiscal year during the term of employment, the Executive shall be eligible to receive a bonus in the amount of $125,000.00 with a target payout at plan of forty-one percent (50%) of annual salary, if any, as may be determined from time to time by the Board in its discretion. The Annual Bonus shall be paid by the Company to the Executive promptly after determination that the relevant targets, attached hereto on Schedule A, have been met, it being understood that the attainment of any financial targets associated with any bonus shall not be determined until following the completion of the Company’s annual audit and public announcement of such results and shall be paid promptly following the Company’s announcement of earnings. In the event that the Compensation Committee is unable to act or if there shall be no such Compensation Committee, then all references herein to the Compensation Committee (except in the proviso to this sentence) shall be deemed to be references to the Board. Upon his termination from employment, the Executive shall be entitled to receive a pro-rata portion of the Annual Bonus calculated based upon his final day of employment, regardless of whether he is employed by the Parent through the conclusion of the fiscal quarter or year, as the case may be, on which the Annual Bonus is based.

Severance Compensation:

governing such options, until the earlier of (A) a period of one (1) year after the Executive’s death or (B) the original term of the option, if such Share Awards is an option.

The Executive may continue coverage with respect to the Company’s group health plans as permitted by the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) for himself and each of his “Qualified Beneficiaries” as defined by COBRA (“COBRA Coverage”). The Company shall reimburse the amount of any COBRA premium paid for COBRA Coverage timely elected by and for the Executive and any Qualified Beneficiary of the Executive, and not otherwise reimbursed, during the period that ends on the earliest of (x) the date the Executive or the Qualified Beneficiary, as the case may be, ceases to be eligible for COBRA Coverage, (y) the last day of the consecutive eighteen (18) month period following the date of the Executive’s termination of employment and (z) the date the Executive or the Qualified Beneficiary, as the case may be, is covered by another group health plan. To reimburse any COBRA premium payment under this paragraph, the Company must receive documentation of the COBRA premium payment within ninety (90) days of its payment.

7. Clawback Rights. The Annual Bonus, and any and all stock based compensation (such as options and equity awards) (collectively, the “Clawback Benefits”) shall be subject to “Clawback Rights” as follows: during the period that the Executive is employed by the Company and upon the termination of the Executive’s employment and for a period of three (3) years thereafter, if there is a restatement of any financial results from which any Clawback Benefits to the Executive shall have been determined, the Executive agrees to repay any amounts which were determined by reference to any Company financial results which were later restated (as defined below), to the extent the Clawback Benefits amounts paid exceed the Clawback Benefits amounts that would have been paid, based on the restatement of the Company’s financial information. All Clawback Benefits amounts resulting from such restated financial results shall be retroactively adjusted by the Compensation Committee to take into account the restated results, and any excess portion of the Clawback Benefits resulting from such restated results shall be immediately surrendered to the Company and if not so surrendered within ninety (90) days of the revised calculation being provided to the Executive by the Compensation Committee following a publicly announced restatement, the Company shall have the right to take any and all action to effectuate such adjustment. The calculation of the revised Clawback Benefits amount shall be determined by the Compensation Committee in good faith and in accordance with applicable law, rules and regulations. All determinations by the Compensation Committee with respect to the Clawback Rights shall be final and binding on the Company and the Executive. The Clawback Rights shall terminate following a Change of Control as defined in Section 11(f), subject to applicable law, rules and regulations. For purposes of this Section 7, a restatement of financial results that requires a repayment of a portion of the Clawback Benefits amounts shall mean a restatement resulting from material non-compliance of the Company with any financial reporting requirement under the federal securities laws and shall not include a restatement of financial results resulting from subsequent changes in accounting pronouncements or requirements which were not in effect on the date the financial statements were originally prepared (“Restatements”). The parties acknowledge it is their intention that the foregoing Clawback Rights as relates to Restatements conform in all respects to the provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (“Dodd-Frank Act”) and require recovery of all “incentive-based” compensation, pursuant to the provisions of the Dodd-Frank Act and any and all rules and regulations promulgated thereunder from time to time in effect. Accordingly, the terms and provisions of this Agreement shall be deemed automatically amended from time to time to assure compliance with the Dodd-Frank Act and such rules and regulations as hereafter may be adopted and in effect.

8. Expenses. The Executive shall be entitled to prompt reimbursement by the Company for all reasonable ordinary and necessary travel, entertainment, and other expenses incurred by the Executive while employed (in accordance with the policies and procedures established by the Company for its senior executive officers) in the performance of his duties and responsibilities under this Agreement; provided, that the Executive shall properly account for such expenses in accordance with Company policies and procedures. Expenses of the Executive in an amount exceeding Two Thousand Five Hundred Dollars and No Cents ($2,500) shall require approval from the Board.

10. Vacation. During the term of this Agreement, the Executive shall be entitled to accrue, on a pro rata basis, twenty (20) paid vacation days per year. Vacation shall be taken at such times as are mutually convenient to the Executive and the Company and no more than ten (10) consecutive days shall be taken at any one time without Company approval in advance.

11. Termination of Employment:

(b) Disability. In the event that, during the term of this Agreement the Executive shall be prevented from performing his essential functions hereunder to the full extent required by the Company by reason of Disability (as defined below), this Agreement and the Executive’s employment with the Company shall automatically terminate. The Company’s obligation to the Executive under such circumstances shall be those set forth in Section 6 regarding severance compensation. For purposes of this Agreement, “Disability” shall mean a physical or mental disability that prevents the performance by the Executive, with or without reasonable accommodation, of his essential functions hereunder for an aggregate of ninety (90) days or longer during any twelve (12) consecutive months. The determination of the Executive’s Disability shall be made by an independent physician who is reasonably acceptable to the Company and the Executive (or his representative), be final and binding on the parties hereto and be made taking into account such competent medical evidence as shall be presented to such independent physician by the Executive and/or the Company or by any physician or group of physicians or other competent medical experts employed by the Executive and/or the Company to advise such independent physician.

(c)

Cause.

(1) At any time during the Employment Period, the Company may terminate this Agreement and the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean: (a) the willful and continued failure of the Executive to perform substantially his duties and responsibilities for the Company (other than any such failure resulting from the Executive’s death or Disability) after a written demand by the Board for substantial performance is delivered to the Executive by the Company, which specifically identifies the manner in which the Board believes that the Executive has not substantially performed his duties and responsibilities, which willful and continued failure is not cured by the Executive within thirty (30) days following his receipt of such written demand; (b) the conviction of, or plea of guilty or nolo contendere to, a felony, or (c) fraud, dishonesty or gross misconduct which is materially and demonstratively injurious to the Company. Termination under clauses (b) or (c) of this Section 11(c)(1) shall not be subject to cure.

(2) For purposes of this Section 11(c), no act, or failure to act, on the part of the Executive shall be considered “willful” unless done, or omitted to be done, by him in bad faith and without reasonable belief that his action or omission was in, or not opposed to, the best interest of the Company. Between the time the Executive receives written demand regarding substantial performance, as set forth in subparagraph (1) above, and prior to an actual termination for Cause, the Executive will be entitled to appear (with counsel) before the full Board to present information regarding his views on the Cause event. After such hearing, termination for Cause must be approved by a majority vote of the full Board (other than the Executive). After providing the written demand regarding substantial performance, the Board may suspend the Executive with full pay and benefits until a final determination by the full Board has been made.

(3) Upon termination of this Agreement for Cause, the Company shall have no further obligations or liability to the Executive or his heirs, administrators or executors with respect to compensation and benefits thereafter, except for the obligation to pay the Executive any Base Salary earned through the date of termination to be paid according to Section 4; any unpaid Annual Bonus to be paid according to Section 5; reimbursement of any and all reasonable expenses paid or incurred by the Executive in connection with and related to the performance of his duties and responsibilities for the Company during the period ending on the termination date to be paid according to Section 8; and any accrued but unused vacation time through the termination date in accordance with Company policy. The Company shall deduct, from all payments made hereunder, all applicable taxes, including income tax, FICA and FUTA, and other appropriate deductions, including expenses.

(d)

For Good Reason or a Change of Control or Without Cause.

(1) At any time during the term of this Agreement and subject to the conditions set forth in Section 12(d)(2) below the Executive may terminate this Agreement and the Executive’s employment with the Company for “Good Reason” or for a “Change of Control” (as defined in Section 12(f)). For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following events without Executive’s consent: (A) the assignment to the Executive of duties that are significantly different from, and/or that result in a substantial diminution of, the duties that he assumed on the Effective Date (including reporting to anyone other than solely and directly to the Board); (B) the assignment to the Executive of a title that is different from and subordinate to the title Chief Operations Officer of the Company; provided, however, for the absence of doubt following a Change of Control, should the Executive be required to serve in a diminished capacity in a division or unit of another entity (including the acquiring entity), such event shall constitute Good Reason regardless of the title of the Executive in such acquiring company, division or unit; or (C) material breach by the Company of this Agreement.

(e) Without “Good Reason” by the Executive. At any time during the term of this Agreement, the Executive shall be entitled to terminate this Agreement and the Executive’s employment with the Company without Good Reason and other than for a Change of Control by providing prior written notice of at least thirty (30) days to the Company. Upon termination by the Executive of this Agreement or the Executive’s employment with the Company without Good Reason and other than for a Change of Control, the Company shall have no further obligations or liability to the Executive or his heirs, administrators or executors with respect to compensation and benefits thereafter, except for the obligation to pay the Executive any Base Salary earned through the date of termination to be paid according to Section 4; reimbursement of any and all reasonable expenses paid or incurred by the Executive in connection with and related to the performance of his duties and responsibilities for the Company during the period ending on the termination date to be paid according to Section 8; and any accrued but unused vacation time through the termination date in accordance with Company policy. The Company shall deduct, from all payments made hereunder, all applicable taxes, including income tax, FICA and FUTA, and other appropriate deductions.

(f) Change of Control. For purposes of this Agreement, “Change of Control” shall mean the occurrence of any one or more of the following: (i) the accumulation (if over time, in any consecutive twelve (12) month period), whether directly, indirectly, beneficially or of record, by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) of more than fifty percent (50%) or more of the shares of the outstanding Common Stock of the Company, whether by merger, consolidation, sale or other transfer of shares of Common Stock (other than a merger or consolidation where the stockholders of the Company prior to the merger or consolidation are the holders of a majority of the voting securities of the entity that survives such merger or consolidation), (ii) a sale of all or substantially all of the assets of the Company or (iii) during any period of twelve (12) consecutive months, the individuals who, at the beginning of such period, constitute the Board, and any new Board member whose election by the Board or nomination for election by the Company’s owners was approved by a vote of at least two-thirds (2/3) of the members of the Board then still in office who either were members of the Board at the beginning of the twelve (12) month period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the Board; provided that the following acquisitions shall not constitute a Change of Control for the purposes of this Agreement: any acquisition of Common Stock or securities convertible into Common Stock by any employee benefit plan (or related trust) sponsored by or maintained by the Company.

(g) Any termination of the Executive’s employment by the Company or by the Executive (other than termination by reason of the Executive’s death) shall be communicated by written Notice of Termination to the other party of this Agreement. For purposes of this Agreement, a “Notice of Termination” shall mean a written notice which shall indicate the specific termination provision in this Agreement relied upon and shall set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive’s employment under the provision so indicated, provided, however, failure to provide timely notification shall not affect the employment status of the Executive.

12. Confidential Information.

(a) Disclosure of Confidential Information. The Executive recognizes, acknowledges and agrees that he has had and will continue to have access to secret and confidential information regarding the Company, its subsidiaries and their respective businesses (“Confidential Information”), including but not limited to, its products, methods, formulas, software code, patents, sources of supply, customer dealings, data, know-how, trade secrets and business plans, provided such information is not in or does not hereafter become part of the public domain, or become known to others through no fault of the Executive. The Executive acknowledges that such information is of great value to the Company, is the sole property of the Company, and has been and will be acquired by him in confidence. In consideration of the obligations undertaken by the Company herein, the Executive will not, at any time, during or after his employment hereunder, reveal, divulge or make known to any person, any information acquired by the Executive during the course of his employment, which is treated as confidential by the Company, and not otherwise in the public domain. The provisions of this Section 12 shall survive the termination of the Executive’s employment hereunder. The Executive affirms that he does not possess and will not rely upon the protected trade secrets or confidential or proprietary information of any prior employer(s) in providing services to the Company or its subsidiaries.

(b) In the event that the Executive’s employment with the Company terminates for any reason, the Executive shall deliver forthwith to the Company any and all originals and copies, including those in electronic or digital formats, of Confidential Information; provided, however, the Executive shall be entitled to retain (i) papers and other materials of a personal nature, including, but not limited to, photographs, correspondence, personal diaries, calendars and rolodexes, personal files and phone books, (ii) information showing his compensation or relating to reimbursement of expenses, (iii) information that he reasonably believes may be needed for tax purposes and (iv) copies of plans, programs and agreements relating to his employment, or termination thereof, with the Company. The covenants and agreements in this Section 12 shall exclude information (A) which is in the public domain through no unauthorized act or omission of Executive or (B) which becomes available to Executive on a non-confidential basis from a source other than the Company or its affiliates without breach of such source’s confidentiality or non-disclosure obligations to the Company or any of its affiliates.

13.

Non-Competition and Non-Solicitation.

(a) The Executive agrees and acknowledges that the Confidential Information that the Executive has already received and will receive is valuable to the Company and that its protection and maintenance constitutes a legitimate business interest of the Company, to be protected by the non-competition restrictions set forth herein. The Executive agrees and acknowledges that the non-competition restrictions set forth herein are reasonable and necessary and do not impose undue hardship or burdens on the Executive. The Executive also acknowledges that the Company’s business is conducted worldwide (the “Territory”), and that the Territory, scope of prohibited competition, and time duration set forth in the non-competition restrictions set forth below are reasonable and necessary to maintain the value of the Confidential Information of, and to protect the goodwill and other legitimate business interests of, the Company, its affiliates and/or its clients or customers. The provisions of this Section 13 shall survive the termination of the Executive’s employment hereunder for the time periods specified below.

(1) Engage, own, manage, operate, control, be employed by, consult for, participate in, or be connected in any manner with the ownership, management, operation or control of any business in competition with the business of the Company.

(2) Recruit, solicit or hire, or attempt to recruit, solicit or hire, any employee, or independent contractor of the Company to leave the employment (or independent contractor relationship) thereof, whether or not any such employee or independent contractor is party to an employment agreement, for the purpose of competing with the business of the Company;

(3) Attempt in any manner to solicit or accept from any customer of the Company, with whom Executive had significant contact during Executive’s employment by the Company (whether under this Agreement or otherwise), business of the kind or competitive with the business done by the Company with such customer or to persuade or attempt to persuade any such customer to cease to do business or to reduce the amount of business which such customer has customarily done or might do with the Company, or if any such customer elects to move its business to a person other than the Company, provide any services of the kind or competitive with the business of the Company for such customer, or have any discussions regarding any such service with such customer, on behalf of such other person for the purpose of competing with the business of the Company; or

(4) Interfere with any relationship, contractual or otherwise, between the Company and any other party, including, without limitation, any supplier, distributor, co-venturer or joint venturer of the Company, for the purpose of soliciting such other party to discontinue or reduce its business with the Company for the purpose of competing with the business of the Company.

With respect to the activities described in Paragraphs (1), (2), (3) and (4) above, the restrictions of this Section 13(b) shall continue during the Term of this Agreement and for a period of one (1) year thereafter.

14. Work Product

(d) The provisions of this Section 14 shall survive the termination or expiration of this Agreement.

15. Miscellaneous.

(b) During the term of this Agreement, the Company (i) shall indemnify and hold harmless the Executive and his heirs and representatives to the maximum extent provided by the laws of the State of Delaware and by Company’s Operating Agreement and (ii) shall cover the Executive under the Company’s directors’ and officers’ liability insurance on the same basis as it covers other senior executive officers and directors of the Company.

(d) This Agreement shall inure to the benefit of, be binding upon and enforceable against, the parties hereto and their respective successors, heirs, beneficiaries and permitted assigns.

(e) The headings contained in this Agreement are for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement.

(f) All notices, requests, demands and other communications required or permitted to be given hereunder shall be in writing and shall be deemed to have been duly given when personally delivered, sent by registered or certified mail, return receipt requested, postage prepaid, or by reputable national overnight delivery service (e.g., Federal Express) for overnight delivery to the party at the address set forth in the preamble to this Agreement, or to such other address as either party may hereafter give the other party notice of in accordance with the provisions hereof. Notices shall be deemed given on the sooner of the date actually received or the third business day after deposited in the mail or one business day after deposited with an overnight delivery service for overnight delivery.

(g) This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, and each of the parties hereto irrevocably consents to the jurisdiction of the Chancery Court of the State of Delaware and venue of the federal and state courts located in the State of New York, County of New York, for any disputes arising out of this Agreement, or the Executive’s employment with the Company. The prevailing party in any dispute arising out of this Agreement shall be entitled to his or its reasonable attorney’s fees and costs.

(h) This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one of the same instrument. The parties hereto have executed this Agreement as of the date set forth above.

(i) The Executive represents and warrants to the Company, that he has the full power and authority to enter into this Agreement and to perform his obligations hereunder and that the execution and delivery of this Agreement and the performance of his obligations hereunder will not conflict with any agreement to which the Executive is a party.

(j) The Company represents and warrants to the Executive that it has the full power and authority to enter into this Agreement and to perform its obligations hereunder and that the execution and delivery of this Agreement and the performance of its obligations hereunder will not conflict with any agreement to which the Company is a party.

[Signature page follows immediately]

IN WITNESS WHEREOF, the Executive and the Company have caused this Executive Employment Agreement to be executed as of the date first above written.

HEATHTECH SOLUTIONS, INC.

By: /s/ Edward Swanson

AUTHORIZED SIGNATURE

By: Edward Swanson

Title: Chief Executive Officer

Date: 6/28/21

EXECUTIVE

/s/ Bradley K. Mathis

Name: Bradley K. Mathis

Date: 6/28/21

SCHEDULE A

ANNUAL BONUS TARGETS

Completion of the following tasks within the Executive’s initial Employment Period shall entitle the Executive to the monetary bonus as described in Section 5(a) herein:

Milestones:

Establish executable goals and timelines for target company to advance asset/s towards approval or commercialization.

Consistently communicate progress and status updates to either BOD or CEO of HLTT or Parent company.

Assist target company in developing a commercialization strategy to advance the asset.

Establish operational infrastructure for target company to sustain ongoing execution of the target strategy.

Monitor target company for progress against the objectives established in the strategy.

EX-99 5 ex991.htm EXHIBIT 99.1

Healthtech Solutions, Inc. Bolsters Management and Board with Two New Appointments

Brad K. Mathis appointed as Chief Operating Officer

Ryan Salomone appointed to Board of Directors

NEW YORK (July 1, 2021) -- via InvestorWire – Healthtech Solutions, Inc. (OTC: HLTT) (“Healthtech” or the “Company”), an innovative portfolio-model life sciences company focused on building impactful solutions for patients and the healthcare system through its subsidiary companies ranging in stage from pre-clinical to commercial growth, announced today that Brad Mathis was named Chief Operating Officer (COO) and Ryan Salomone was appointed to the Board of Directors. Brad Mathis and Ryan Salomone have extensive backgrounds that make them uniquely positioned to bring substantial value to Healthtech.

Brad Mathis brings a diversified skillset to Healthtech, acquired from over 30 years in the pharmaceutical and biotech industry. He most recently served as the Vice President and General Manager of the US Neurology Franchise for Argenx Inc. Prior to Argenx, he held several Vice President and General Manager jobs in the startup biotechnology industry in Neurometabolics, Hematology and Gene Therapy. At Alexion, Brad held multiple positions of increasing responsibility heading up sales, marketing, market access, and training. In addition to his extensive leadership experience, Brad has executed numerous successful product launches, overseeing multiple cross-functional teams, and ensuring critical timebound tactics supported timely product launches. Before joining Alexion, Brad held several positions of increasing responsibility with Amgen, Celgene, Biogen and BMS over a span of 15 years.

“It is an honor to be joining Ned Swanson, MD, and the Healthtech team to identify, develop and accelerate new technologies in the healthcare industry,” stated newly appointed COO Brad Mathis, who continued, “This is truly a rare opportunity to leverage my life’s experience in a role that can positively impact the lives of patients and providers. With over 30 years of biotech commercialization and operations experience, I am positioned to help startup companies develop and mature to bring game changing assets to market. We believe our portfolio model allows us to align synergies across assets while taking advantage of the unique skillsets and experience of our leadership team.”

Ryan Salomone brings an invaluable background to the board of Healthtech, with over 15 years of experience working at Fidelity Institutional Asset Management focused on healthcare investing, most recently as a Senior Healthcare Analyst on the Small Cap Team. Mr. Salomone’s experience at Fidelity is directly applicable to Healthtech’s strategy, including a systematic approach to evaluating new opportunities, leveraging his insights to accelerate portfolio companies, and leaning on his broad network of investment and industry relationships to take Healthtech and its subsidiaries to their full potential. Since leaving Fidelity, Mr. Salomone co-founded Twin Keel Capital, an asset management firm focused on systematically managed investment strategies, where he serves as the chief investment officer (CIO). Ryan’s insights from developing the systematic investing approach at Twin Keel Capital will further bolster the evaluation and diligence processes at Healthtech.

“I could not be more thrilled to be joining Healthtech’s Board of Directors. Healthtech’s unique model offers the potential for meaningful value creation for both portfolio companies and investors while striving to achieve the ultimate goal of improving patients’ lives,” said newly appointed director Ryan Salomone. “I am humbled to be working with and advising such an accomplished collection of healthcare executives that possess the deep domain knowledge necessary to take innovative healthcare assets to the next level. I am confident that my 16 years of capital market experience cultivating industry relationships and performing deep due diligence, risk assessment, and valuation analysis on healthcare assets will prove to be a material benefit to Healthtech achieving its mission.”

Ned Swanson, MD, CEO of Healthtech commented, “We could not be more thrilled to have Brad Mathis as our COO and Ryan Salomone as a director of Healthtech. Their additions significantly expand our capabilities to accelerate the next advancements in healthcare with the potential to improve the lives of countless individuals. With Brad’s experience leading assets from pre-commercial stage to greater than $1.5 billion in revenue and Ryan’s experience advising funds at Fidelity with greater than $35 billion in assets under management, we know we have the right people to deliver on our vision at Healthtech.”

About Healthtech Solutions Inc.

Healthtech Solutions Inc. is an innovative portfolio-model life sciences company focused on building impactful solutions for patients and the healthcare system through our subsidiary companies ranging in stage from pre-clinical to commercial growth. At Healthtech, we are driven by innovation and people. At the core, our philosophy is that highly motivated people with ambitious goals can achieve breakthroughs with the right organizational support. By identifying and building visionary teams within an ecosystem that fuels their strengths, we believe that we can collectively accelerate the next wave of advancements in healthcare. From our perspective, breakthroughs often occur at the intersection of multiple approaches, so we are agnostic to the solution - therapeutics, devices, diagnostics, digital technology, or a combination. In fact, we hypothesize that some of the most promising breakthroughs will occur at the interface of these traditional silos, which has already begun to occur. Healthcare, illness, and injury are multifactorial, and we believe the solutions often need to be multi-pronged to succeed.

NO OFFER OR SOLICITATION

This communication shall neither constitute an offer to sell nor the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

FORWARD-LOOKING STATEMENTS

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company’s future plans, strategies and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek” or “project” or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates, and assumptions, and are subject to several risks and uncertainties and other influences, over many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.

Contacts:

Investors
IR@hltt.tech

Corporate and Media Communications:

inquiries@hltt.tech

844-926-3399

www.healthtech-solutions.com

EX-101.SCH 6 hltt-20210628.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 hltt-20210628_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 hltt-20210628_pre.xml XBRL PRESENTATION FILE XML 9 hltt8k62821_htm.xml IDEA: XBRL DOCUMENT 0001307624 2021-06-28 2021-06-28 iso4217:USD shares iso4217:USD shares 0001307624 false 8-K 2021-06-28 HEALTHTECH SOLUTIONS, INC./UT UT 0-51012 84-2528660 181 Dante Avenue Tuckahoe NY 10707 844 926-3399 false false false false false XML 10 R1.htm IDEA: XBRL DOCUMENT

Cover	Jun. 28, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 28, 2021
Entity File Number	0-51012
Entity Registrant Name	HEALTHTECH SOLUTIONS, INC./UT
Entity Central Index Key	0001307624
Entity Tax Identification Number	84-2528660
Entity Incorporation, State or Country Code	UT
Entity Address, Address Line One	181 Dante Avenue
Entity Address, City or Town	Tuckahoe
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10707
City Area Code	844
Local Phone Number	926-3399
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "*6WE('04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " BEMY2CE8O?^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$Y&82;-I:.G#@8K;.QF;+4UBQ-C:R1]^SE>FS*V!]C1TN]/ MGT"-]E(/ 9_#X#&0Q7@WN:Z/4OLU.Q%Y"1#U"9V*94KTJ7D8@E.4GN$(7ND/ M=42H.%^!0U)&D8(96/B%R-K&:*D#*AK"!6_T@O>?H_"V@68J[^BQ'.N<2SL(>'O:O>1U"]M' M4KW&]"M:26>/:W:=_%IO'O=;UE:\$@5?%37?5Y6\?Y!621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M "*6WE(!^DGSR0, %\. 8 >&PO=V]R:W-H965T&UL ME9==<^(V%(:O=W^%QM<6*J&(N31"2:+Y9NB,Z9<[/P_(G_A- M\+TY:Y-L*&NE7K/.+!PZ7D;$(Q[83(+!WQN?\"C*E(#C[Z.H4[PS"SQOG]3O M\\'#8-;,\(F*?HC0[H9.SR$AW[ TLL]J_\"/ VIG>H&*3/Y+]H=G6RV'!*FQ M*CX& T$LY.&?O1\3<1;0]"X$^,< /^<^O"BG_,HL&PVTVA.=/0UJ62,?:AX- M<$)F55E:#7<%Q-G11+UQ/7 M2&47W. 8=G<(\R^$_9K*6^+W;HCO^?3?X2X0 M%!A^@>'G>DT,@_PY7ANKH5!_(9+-0K*92[8N2'Y500K3QY+51\*K1HB']QK? M$(A6 =%"5<9 $.84]Q';5E'@\1L6&8YPM N.]G7)6' M5$BF,B0P7RKS@BN= M*O_YTZ>:VG<*M@ZJ.)56V ]R+R).YFF\KIZ/N(;7:%./^@A-MZ#I7D/SS+3:?W+HO*X2S5W#VKN&< M0%$UB\A,AOR=?.,?5:2XDN=YM.EU.WX+P>H76/UKL%;LG[(4L+BX$H328JA81"7E586?0: M=;2T],R4Z360XS#4W)B;4X,\PG/D25:3X9*T1V'%2QCE^(W+%#,56KHV]?\7 MYR3K0197:B\K&7&Y51J\LIU"V4K[I[B!_\Q6E'BAU9N00742<U^MB;.5&07%_STLXA@^\RRBX0*^%^0@M=P6* M6_JC"B GBYV2V+90(]+W.XUFL]_'B,J=@>*6_D,+:[F$Q,1Q*H^^9BJI<*&Z M79V6FP#%O7NI(A$(*^26?(?IK06+*GEPE5J>TOTI;M8+S1L!I(?#^CI\?,'W M#WS9/6TV%^J'Z]61^:7O^[@S_X=L9DP*9'6 -;*U@*7G^U=Y_C3F>IO5\Q=0 ML+MLLB5,5F[K-8(7T=RSXT)V]/K.LC<:$O$-"'FW75C@^G":.72L2O(3Q%I9 M.(_DS1V< +G.'H#[&Z7LJ9,=2HHSY>@?4$L#!!0 ( "*6WE*?H!OPL0( M .(, - >&PO9KEMWDOSAR+DC MO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-B MK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@ MI+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTP MY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36 M-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO M<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#V MG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ M+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /, M)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AME ML,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>> MQ[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( M "*6WE*7BKL
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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://healthtech.com/role/Cover Cover Cover 1 false false All Reports Book All Reports hltt8k62821.htm ex10a.htm ex10b.htm ex10c.htm ex991.htm hltt-20210628.xsd hltt-20210628_lab.xml hltt-20210628_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hltt8k62821.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "hltt8k62821.htm" ] }, "labelLink": { "local": [ "hltt-20210628_lab.xml" ] }, "presentationLink": { "local": [ "hltt-20210628_pre.xml" ] }, "schema": { "local": [ "hltt-20210628.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "HLTT", "nsuri": "http://healthtech.com/20210628", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "hltt8k62821.htm", "contextRef": "From2021-06-28to2021-06-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://healthtech.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "hltt8k62821.htm", "contextRef": "From2021-06-28to2021-06-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthtech.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 17 0001262463-21-000305-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001262463-21-000305-xbrl.zip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end